<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vsp</journal-id><journal-title-group><journal-title xml:lang="ru">Вопросы современной педиатрии</journal-title><trans-title-group xml:lang="en"><trans-title>Current Pediatrics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-5527</issn><issn pub-type="epub">1682-5535</issn><publisher><publisher-name>Издательство «ПедиатрЪ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">vsp-744</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group></article-categories><title-group><article-title>ОПЫТ ПРИМЕНЕНИЯ МИКОФЕНОЛАТА МОФЕТИЛА У БОЛЬНОГО СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ</article-title><trans-title-group xml:lang="en"><trans-title>USE OF MYCOPHENOLATE MOPHETYL IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Валиева</surname><given-names>С.И.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Е.И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alexeeva</surname><given-names>E.I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Александров</surname><given-names>А.Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Aleksandrov</surname><given-names>A.E.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Добровольский</surname><given-names>А.Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Dobrovolsky</surname><given-names>A.E.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научный центр здоровья детей РАМН, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>08</day><month>09</month><year>2015</year></pub-date><volume>5</volume><issue>3</issue><issue-title>Вопросы современной педиатрии</issue-title><fpage>88</fpage><lpage>92</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Валиева С., Алексеева Е., Александров А., Добровольский А., 2006</copyright-statement><copyright-year>2006</copyright-year><copyright-holder xml:lang="ru">Валиева С., Алексеева Е., Александров А., Добровольский А.</copyright-holder><copyright-holder xml:lang="en">Валиева С., Alexeeva E., Aleksandrov A., Dobrovolsky A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vsp.spr-journal.ru/jour/article/view/744">https://vsp.spr-journal.ru/jour/article/view/744</self-uri><abstract><p>В статье представлен клинический случай применения микофенолата мофетила у больного с высокоактивной СКВ и люпус-нефритом. Заболевание характеризовалось высокой активностью, агрессивным течением, быстрым развитием почечной недостаточности, полиорганным поражением и развитием антифосфолипидного синдрома. Активное лечение, включавшее синхронную терапию, глюкокортикоиды и препараты, улучшающие кровообращение (пентоксифиллин, дипиридамол, гепарин), переливание внутривенного иммуноглобулина, недостаточно снижало активность заболевания. Назначение микофенолата мофетила позволило значительно снизить активность аутоиммунного процесса в течении двух недель после назначения, а в дальнейшем добиться развития клинико-лабораторной ремиссии. </p><p>Ключевые слова: системная красная волчанка, микофенолота мофетил, дети, лечение.(Вопросы современной педиатрии. – 2006;5(3):88-92)</p></abstract><trans-abstract xml:lang="en"><p>The article reports a case of highly active SLE and lupusbnephritis in a 15 years old boy, who was treated with mycophenolate mophetyl the case was notable for high activity and aggressive course of the disease with rapid development of renal unsufficiency, polyorganic unsufficiency and antiphospholipid syndrome. Although the patient received an appropriate active therapy, including synchronized therapy (consisting of timebrelated plasmopherresis and infusions of cyclophosphamide and metyl prednisolone), glucocorticoides, preparations improving blood circulation (pentoxyphillin, dipiridamol, heparine), intravenous immunoglobulins, the disease activity control was unsufficient. The administration of mycophenolate mophetyl has led to diminuition of the disease activity, which was registered at the end of the second week of treatment, and finally has reached a level of clinical and laboratoty remission of the disease.</p><p>Key words: systemic lupus erythematosus, mycophenolate mophetyl, children, treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>микофенолота мофетил</kwd><kwd>дети</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>mycophenolate mophetyl</kwd><kwd>children</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
